Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
162
datasets available to search
ShareScore release 0.9.0
Dataset results
162 results for “Alzheimer disease (AD)”
Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis
ClinicalTrials.gov study NCT04850053. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
ClinicalTrials.gov study NCT04685590. IPD Sharing: NO. Countries: 2. Publications: 2.
Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Health
ClinicalTrials.gov study NCT03417986. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease
ClinicalTrials.gov study NCT01297218. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: White matter hyperintensities and CSF AD biomarkers in preclinical Alzheimer's disease
Objective: Recent studies suggest that white matter hyperintensities (WMH) on MRI, which primarily reflect small vessel cerebrovascular disease, may play a role in the evolution of Alzheimer's disease (AD). In a longitudinal study, we investigated whether WMH promote the progression of AD pathology, or alter the association between AD pathology and risk of progression from normal cognition to mild cognitive impairment (MCI). Methods: Two sets of analyses were conducted. The relationship between whole brain WMH load, based on FLAIR MRI images, obtained in initially cognitively normal participants (n=274) and time to onset of symptoms of MCI (n=60) was examined using Cox regression models. In a subset of the participants with both MRI and CSF data (n=204), the interaction of WMH load and CSF AD biomarkers was also evaluated. Results: Baseline WMH load interacted with CSF t-tau with respect to symptom onset, but not with CSF abeta1-42 or p-tau181. WMH volume was associated with time to symptom onset of MCI among individuals with low t-tau [HR=1.35, CI=1.06-1.73, p=0.013], but not those with high t-tau [HR=0.86,CI=0.56-1.32, p=0.47]. The rate of change in the CSF biomarkers over time was not associated with the rate of change in WMH volumes. Conclusions and Relevance: These results suggest that WMH primarily affect the risk of progression when CSF measures of neurodegeneration or neuronal injury (as reflected by t-tau) are low. However, CSF biomarkers of amyloid and p-tau and WMH appear to have largely independent and non-synergistic effects on the risk of progression to MCI.
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT04339413. IPD Sharing: YES. Countries: 17. Publications: 0.
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets
ClinicalTrials.gov study NCT01089582. IPD Sharing: Not stated. Countries: 1. Publications: 0.
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
ClinicalTrials.gov study NCT02284906. IPD Sharing: YES. Countries: 4. Publications: 0.
Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease II (TRANSFORM-AD II)
ClinicalTrials.gov study NCT07230158. IPD Sharing: YES. Countries: 1. Publications: 0.
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT00702143. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT02754830. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT05619692. IPD Sharing: NO. Countries: 2. Publications: 0.
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT04602624. IPD Sharing: NO. Countries: 1. Publications: 0.
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
ClinicalTrials.gov study NCT04730635. IPD Sharing: YES. Countries: 2. Publications: 0.
A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
ClinicalTrials.gov study NCT01565343. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Acupuncture to Reduce Anxiety in Alzheimer's Disease (AD) and AD Related Dementias
ClinicalTrials.gov study NCT03814382. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT02614131. IPD Sharing: Not stated. Countries: 2. Publications: 0.
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT04592341. IPD Sharing: YES. Countries: 8. Publications: 0.
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
ClinicalTrials.gov study NCT03712787. IPD Sharing: YES. Countries: 10. Publications: 0.
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD
ClinicalTrials.gov study NCT01662882. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.